-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From June 4th to 8th, the 57th American Society of Clinical Oncology (ASCO) Annual Meeting will be held online in the form of a virtual meeting.
With the burst of innovation in the field of China's biomedicine, more and more Chinese companies have emerged at the ASCO conference in recent years.
This year, 16 studies from Chinese scholars were selected as oral reports, breaking records.
It is reported that Junshi Biotech's study selected for the plenary meeting is the phase 3 clinical JUPITER-02 study (NCT03581786) of teriprizumab combined with gemcitabine and cisplatin in the first-line treatment of nasopharyngeal carcinoma (NCT03581786), which aims to compare teripril alone The efficacy and safety of anti-combined gemcitabine/cisplatin and placebo combined with gemcitabine/cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.
Picture from Junshi Bio
A total of 289 patients with recurrent/metastatic nasopharyngeal carcinoma who had not received chemotherapy were enrolled in the study, of which 146 were in the combination chemotherapy group with teriprizumab (240 mg, Q3W) and 143 were in the combination chemotherapy group with placebo.
As of the interim analysis date of May 30, 2020, the median treatment duration in decibels for the teriprizumab group and the placebo group was 39 weeks and 36 weeks.
In addition to Junshi's breakthrough research on nasopharyngeal carcinoma, Chinese scholars also brought advances in the treatment of other diseases during the ASCO period.
In terms of breast cancer treatment, a total of 3 studies from Chinese scholars were selected for oral reports, and 2 were from Hengrui Medicine.
In the treatment of esophageal cancer, the popularity of neoadjuvant immunotherapy continues.
In the field of hematology and tumors, the global phase I clinical research results of the Bcl-2 inhibitor lisaftoclax (APG-2575) brought by Ascent Pharmaceuticals show that APG-2575 treats relapsed/refractory (R/R) chronic lymphocytic leukemia/small The objective response rate (ORR) of patients with lymphocytic lymphoma (CLL/SLL) reached 85.
In terms of melanoma, the new small molecule MDM2 inhibitor alrizomadlin (APG-115) of Ascent Pharmaceuticals has brought ORR in a phase 2 clinical study in combination with pembrolizumab to combat unresectable/metastatic melanoma patients who have failed immuno-oncology drug treatment.
Cancer was once regarded as a terminal illness, and with the development of modern medicine, more and more treatment options have brought new options for patients to extend their lives.